Umbilical cord mesenchymal stem cells were assessed in a study carried out under real clinical practice conditions, which followed 120 patients with lupus nephritis unresponsive to conventional therapy for twelve months. Twelve months after infusion, 56.7% showed a positive renal response.
The context: an autoimmune disease that targets the kidneys
Systemic lupus erythematosus (SLE) is an autoimmune condition: the immune system stops recognising the body’s own structures as self and attacks them. When the kidneys are the target, the condition is called lupus nephritis — an inflammatory process that, left uncontrolled, can progress to chronic kidney failure.
Standard treatment remains the combination of corticosteroids and immunosuppressants. Not all patients respond, however: in the forms classified as refractory the range of alternatives narrows considerably, and it is precisely this group the study worked with.
Why umbilical cord mesenchymal stem cells in autoimmune disease
Umbilical cord mesenchymal stem cells (UC-MSCs) do not work like a drug aimed at a single target. The mechanism research focuses on is immunomodulation: restoring balance to a dysregulated immune response rather than shutting it down indiscriminately. The cell source is umbilical cord tissue, one of the biological materials that can be preserved at birth. Cord tissue preservation.
In experimental studies these cells curb the abnormal proliferation of T and B lymphocytes, lower pro-inflammatory cytokine production and promote the expansion of regulatory T cells, whose role is to bring the inflammatory process to a close. Alongside this they exert a trophic action on damaged tissue.
It is an approach conceptually far removed from traditional immunosuppression, and it explains why rheumatology and nephrology are following this line of research with growing attention.
The study: 120 patients treated with umbilical cord mesenchymal stem cells
The study is real-world in design: patients were followed in the ordinary care setting rather than in a tightly controlled experimental one. It therefore lacks a randomised control arm — a stated methodological limitation — but the design reflects how the therapy behaves under conditions close to everyday practice.
The data collected twelve months after infusion:
- Positive renal response, complete or partial, in 56.7% of patients.
- Significant fall in proteinuria — the loss of protein in the urine — the most direct marker of glomerular damage.
- Increase in serum albumin, a complementary indicator of renal function.
- Progressive reduction in prednisone dose, with less exposure to the side effects of prolonged corticosteroid therapy.
This last figure is worth pausing on: in autoimmune disease, being able to lower the steroid is a therapeutic objective in its own right, not a side benefit.
Baseline renal function: why the timing of treatment matters
The most interesting signal comes from the comparison based on renal function at the time of treatment. In patients whose function was still relatively preserved — an eGFR value ≥ 45 ml/min/1.73 m² — the response rate rose to 66.3%, appreciably above the average for the cohort as a whole.
The finding is consistent with the premises of regenerative medicine: mesenchymal cells can modulate inflammation and support repair processes, but they do not regenerate tissue that has already become fibrotic. The therapeutic window exists, and it yields more when organ damage is not yet advanced.
The safety profile of the infusions
Over the course of the study the infusions proved well tolerated: no serious adverse events directly attributable to the stem cells were recorded. This is in line with what has been reported from other UC-MSC experiences in autoimmune settings.
What the study does not demonstrate
Without a randomised control group, not all the improvements observed can be attributed with certainty to the cell therapy. Confirming the size of the effect and establishing optimal dosing and timing will require large-scale controlled studies.
Important note — The applications described belong to the field of clinical research and are not approved therapies in current practice. None of the information provided should be taken as medical advice.
Umbilical cord mesenchymal stem cells: why SSCB follows this research
Lupus nephritis is adult-onset, and the point is worth stating plainly: research on cord-derived stem cells is not confined to paediatrics. Cord mesenchymal cells are currently the subject of more than 300 active clinical trials, from orthopaedics to neurology to autoimmune disease.
SSCB preserves cord blood, cord tissue — the source from which umbilical cord mesenchymal stem cells are obtained — and placenta → “Find out more“.
Source Zheng Y, Liu S, Zeng L, et al. Allogeneic umbilical cord-derived mesenchymal stromal cells for treatment of refractory lupus nephritis: a real-world study. Stem Cell Res Ther. 2026;17:201. doi:10.1186/s13287-026-05021-5
